Iconic Labs Valuation
Is ICON undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ICON when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ICON's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ICON's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ICON?
Key metric: As ICON is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is ICON's PB Ratio? | |
|---|---|
| PB Ratio | -0.2x |
| Book | -UK£2.74m |
| Market Cap | UK£585.98k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ICON's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
TRLS Trellus Health | 0.09x | n/a | UK£1.1m |
PHSC PHSC | 0.9x | n/a | UK£2.9m |
TLY Totally | 0.5x | 148.7% | UK£18.2m |
GENI GENinCode | 2.6x | n/a | UK£7.3m |
ICON Iconic Labs | n/a | n/a | UK£586.0k |
Price-To-Book vs Peers: ICON has negative equity and a Price-To-Book Ratio (-0.2x) compared to the peer average (1.1x).
Price to Book Ratio vs Industry
How does ICON's PB Ratio compare vs other companies in the European Healthcare Industry?
| 4 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 4 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: ICON has negative equity and a Price-To-Book Ratio (-0.2x) compared to the European Healthcare industry average (1.4x).
Price to Book Ratio vs Fair Ratio
What is ICON's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -0.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ICON's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.05
7D
-4.2%
1Y
4.8%
Arjo
SEK 9.2b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 33.52
7D
-5.4%
1Y
-8.8%
Guerbet
€335.4m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€26.70
7D
-9.6%
1Y
50.0%